Beranda › Mieloma Multipel › Iowa › Cedar Rapids
Uji klinis Mieloma Multipel di Cedar Rapids, IA
15 studi untuk Mieloma Multipel mencari peserta di lokasi sekitar Cedar Rapids (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 3
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi jauhnya
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Menerima pesertaFase 1
- Research Site, Iowa City · 25 mi jauhnya
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 3
- University of Iowa Hospital and Clinics, Iowa City · 25 mi jauhnya
Collection of Tissue Samples for Cancer Research
Menerima pesertaStudi observasional
- University of Iowa, Iowa City · 25 mi jauhnya
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 2
- University of Iowa, Iowa City · 25 mi jauhnya
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Menerima pesertaFase 3
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Menerima pesertaFase 1/2
- Research Site, Iowa City · 25 mi jauhnya
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Menerima pesertaFase 3
- Research Site, Iowa City · 25 mi jauhnya
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Menerima pesertaFase 2
- University of Iowa, Iowa City · 25 mi jauhnya
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Menerima pesertaFase 3
- Physicians' Clinic of Iowa PC, Cedar Rapids
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25 mi jauhnya
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Menerima pesertaFase 2
- University of Iowa, Iowa City · 25 mi jauhnya
Sirolimus Pre-conditioning on T Cell Activity and T-cell Engaging Bispecific Antibody Efficacy in Multiple Myeloma
Menerima pesertaFase 1
- University of Iowa Health Care, Iowa City · 25 mi jauhnya
Sleep Apnea in Patients With MGUS and MM
Menerima pesertaStudi observasional
- University of Iowa, Iowa City · 25 mi jauhnya
Activity Levels in Bone Marrow Transplant Patients
Menerima pesertaStudi observasional
- University of Iowa, Iowa City · 25 mi jauhnya
Limited-duration Teclistamab
Menerima pesertaFase 2
- University of Iowa Hospitals and Clinics, Iowa City · 25 mi jauhnya
Uji klinis Mieloma Multipel di kota lain
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
Studi lain di Cedar Rapids
- Kanker Paru Non-Sel Kecil20 studi
- Kanker Payudara17 studi
- Leukemia Mieloid Akut16 studi
- Kanker (semua jenis)15 studi
- Kanker Paru14 studi
- Kanker Kolorektal13 studi
- Kanker Prostat12 studi
- Karsinoma Sel Skuamosa Kepala dan Leher12 studi
- Melanoma10 studi
- Stroke10 studi
- Kanker Metastatik9 studi
- Kanker Endometrium9 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.